Increased Precautions We're Taking in Response to the Coronavirus
As updates on the impact of the coronavirus continue to be released, we want to take a moment to inform you of the heightened preventative measures we have put in place at Duffy's Napa Valley Rehab to keep our patients, their families, and our employees safe. All efforts are guided by and in adherence to the recommendations distributed by the CDC.

Please note that for the safety of our patients, their families, and our staff, on-site visitation is no longer allowed at Duffy's Napa Valley Rehab.

  • This restriction has been implemented in compliance with updated corporate and state regulations to further reduce the risks associated with COVID-19.
  • We are offering visitation through telehealth services so that our patients can remain connected to their loved ones.
  • Alternate methods of communication for other services are being vetted and may be offered when deemed clinically appropriate.

For specific information regarding these changes and limitations, please contact us directly.

CDC updates are consistently monitored to ensure that all guidance followed is based on the latest information released.

  • All staff has received infection prevention and control training.
  • Thorough disinfection and hygiene guidance has been provided.
  • Patient care supplies such as masks and hand sanitizer are being monitored and utilized.
  • Temperature and symptom screening protocols are in place for all patients and staff.
  • Social distancing strategies have been implemented to ensure that patients and staff maintain proper distance from one another at all times.
  • Cleaning service contracts have been reviewed for additional support.
  • Personal protective equipment items are routinely checked to ensure proper and secure storage.
  • CDC informational posters are on display to provide important reminders on proper infection prevention procedures.
  • We are in communication with our local health department to receive important community-specific updates.

The safety of our patients, their families, and our employees is our top priority, and we will remain steadfast in our efforts to reduce any risk associated with COVID-19.

The CDC has provided a list of easy tips that can help prevent the spread of the coronavirus.

  • Avoid close contact with people who are sick.
  • Cover your cough or sneeze with a tissue and then immediately dispose of the tissue.
  • Avoid touching your eyes, nose, and mouth.
  • Clean and disinfect objects and surfaces that are frequently touched.
  • Wash your hands often with soap and water for at least 20 seconds.
  • Stay home when you are sick, except to get medical care.

For detailed information on COVID-19, please visit https://www.cdc.gov/coronavirus/2019-ncov/index.html

Blog

FDA approves Zohydro, first hydrocodone-only painkiller

It’s been a long ride for Zohydro ER and its California-based pharmaceutical firm Zogenix, but the journey is nearing an end.

Zohydro ER will be the first extended-release, hydrocodone-only painkiller to reach the market, expected in approximately four months.

On October 25, the FDA officially approved this highly controversial drug to treat severe chronic pain that is unresponsive to alternative therapies.

The approval came as a surprise since the FDA’s own panel of advisors voted strongly against recommending approval due to Zohydro’s potential for addiction and lack of tamper-resistant technology in December 2012, followed by an unspecified delay in March of this year.

Until now, hydrocodone was only sold in combination with non-addictive analgesics such as aspirin or acetaminophen (as in Vicodin), and the approval drew criticism from safety advocates who wanted anti-abuse design features that would make it harder for users to crush the pills and snort or inject them.

Vicodin contains up to 10 milligrams of hydrocodone, with a daily maximum dosage of around 60 milligrams. Zohydro ER, which would likely be taken twice a day, could result in a daily dosage of up to 100 milligrams.

To balance the needs of patients with chronic pain against the risk of misuse, Zohydro will be classified as a Schedule II controlled substance, which places strict security measures on its prescription, dispensing and use.

To further address the concerns of potential addiction, the FDA is requiring post-marketing studies of Zohydro to assess the risk of abuse, addiction and overdose associated with long-term use beyond 12 weeks.